Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acura's Meth-Impeding Nexafed Pseudoephedrine Could Transform Category

This article was originally published in The Tan Sheet

Executive Summary

Acura Pharmaceuticals hopes its "extraction-resistant" pseudoephedrine hydrochloride tablet can break free of the pharmacy counter to true OTC status, and help protect the popular decongestant ingredient from becoming prescription-only, a top executive said.
Advertisement

Related Content

In Brief
In Brief
State Pseudoephedrine Legislation
Going Green Can Boost Sales And Profits, But Targets Elusive Consumers
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Advertisement
UsernamePublicRestriction

Register

PS105045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel